Panel Rejects BMS Investor's Bid To 'Camouflage A Wolf'
A New Jersey state appeals court said an investor's amended complaint over Bristol-Myers Squibb Co.'s $74 billion acquisition of Celgene Corp. was a wolf camouflaged in sheep's clothing, finding that the...To view the full article, register now.
Already a subscriber? Click here to view full article